Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Study Identifier
MAF/AGN/OPH/GLA/032
CT.gov Identifier
NCT01489670
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • bimatoprost 0.01% ophthalmic solution
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of primary open-angle glaucoma or ocular hypertension * Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy
    Exclusion Criteria:
    * None

    Protocol Summary

    This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.

    Study Locations

    Location
    Status
    Location
    Bülach, Canton of Zurich, Switzerland
    Status
    Not applicable